Work

A phase 3, randomized, open-label study to compare the efficacy of tislelizumab (BGB-A317) versus chemotherapy as second-line therapy for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps3111

Authors: Lin Shen, Jaffer A. Ajani, Sung-Bae Kim, Eric Van Cutsem, Baohong Guo, James Song, Virginia Paton, Ken Kato

Institutions: Peking University Cancer Hospital, The University of Texas MD Anderson Cancer Center, Asan Medical Center, University of Ulsan, Universitair Ziekenhuis Leuven, BeiGene (China), National Cancer Center Hospital

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891039288

Cites:

Cited by: 1

Related to: 10